Patents by Inventor Benjamin J. BRUNO
Benjamin J. BRUNO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969434Abstract: Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.Type: GrantFiled: August 29, 2022Date of Patent: April 30, 2024Inventors: Jonathan Ogle, Benjamin J. Bruno, Kongnara Papangkorn, Samuel Akapo, Joel Frank, Nachiappan Chidambaram, Mahesh V. Patel
-
Publication number: 20240124285Abstract: A lift device includes a base, a platform, and a scissor assembly coupling the base to the platform. The scissor assembly includes a first scissor layer, a second scissor layer, and a third scissor layer each including an inner arm pivotally coupled to an outer arm. The first scissor layer has a first middle axis offset vertically from a first end axis center point. A kicker assembly couples an actuator configured to raise and lower the platform to the second scissor layer and the third scissor layer. The kicker assembly includes a kicker with opposing first and second kicker ends. The kicker is pivotally coupled to the second scissor layer and releasably coupled to the third scissor layer. The actuator rotates the kicker relative to the second scissor layer. A guide is coupled to the kicker and configured to limit the rotation of the kicker.Type: ApplicationFiled: October 17, 2022Publication date: April 18, 2024Applicant: Oshkosh CorporationInventors: Mark G. Neubauer, Benjamin C. Bruno, Devin J. Rosencrance, Patrick Dingman
-
Patent number: 11945702Abstract: A lift device includes a base, a platform, and a scissor assembly coupling the base to the platform. The scissor assembly includes a first scissor layer, a second scissor layer, and a third scissor layer each including an inner arm pivotally coupled to an outer arm. The first scissor layer has a first middle axis offset vertically from a first end axis center point. A kicker assembly couples an actuator configured to raise and lower the platform to the second scissor layer and the third scissor layer. The kicker assembly includes a kicker with opposing first and second kicker ends. The kicker is pivotally coupled to the second scissor layer and releasably coupled to the third scissor layer. The actuator rotates the kicker relative to the second scissor layer. A guide is coupled to the kicker and configured to limit the rotation of the kicker.Type: GrantFiled: October 17, 2022Date of Patent: April 2, 2024Assignee: Oshkosh CorporationInventors: Mark G. Neubauer, Benjamin C. Bruno, Devin J. Rosencrance, Patrick Dingman
-
Publication number: 20230390304Abstract: Disclosed is a method and composition for treating CNS disorders in a subject. In an embodiment, the method preferably comprises the ordered steps of identifying a subject having or being predisposed to epilepsy, and orally administering to the subject an AED. The administration preferably comprises an administration regimen of a predetermined quantity of the AED, at a predetermined frequency, and for a predetermined duration. The subject preferably comprises a subject experiencing seizure clusters, WWE, and more especially a WWE of childbearing age. The composition preferably comprises a NAS, and more especially an ENAS. The method preferably results in the prevention, or reduced frequency or magnitude of epileptic seizures.Type: ApplicationFiled: June 2, 2023Publication date: December 7, 2023Applicant: Lipocine Inc.Inventors: Benjamin J. Bruno, Nachiappan Chidambaram, Jonathan Ogle, Kongnara Papangkorn, Mahesh V. Patel
-
Publication number: 20230101470Abstract: An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.Type: ApplicationFiled: October 27, 2021Publication date: March 30, 2023Applicant: Lipocine Inc.Inventors: Kilyoung Kim, Nachiappan Chidambaram, Mahesh V. Patel, Benjamin J. Bruno, Shadi Mehraban
-
Publication number: 20220354867Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: ApplicationFiled: May 10, 2022Publication date: November 10, 2022Applicant: Lipocine Inc.Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 11478485Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: May 10, 2022Date of Patent: October 25, 2022Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 11337987Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.Type: GrantFiled: May 7, 2021Date of Patent: May 24, 2022Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
-
Patent number: 10494417Abstract: In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 25, 2015Date of Patent: December 3, 2019Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Carol Lim, Benjamin J. Bruno, Geoffrey D. Miller, Andrew S. Dixon
-
Publication number: 20170174750Abstract: In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: March 25, 2015Publication date: June 22, 2017Inventors: Carol LIM, Benjamin J. BRUNO, Geoffrey D. MILLER, Andrew S. DIXON